323 related articles for article (PubMed ID: 9858941)
1. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.
Mastino A; Favalli C; Grelli S; Rasi G; Pica F; Goldstein AL; Garaci E
Int J Cancer; 1992 Feb; 50(3):493-9. PubMed ID: 1735618
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
[TBL] [Abstract][Full Text] [Related]
5. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
6. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
7. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
Rinehart JJ; Triozzi PL; Lee MH; Aldrich W; Young D
Mol Biother; 1992 Jun; 4(2):77-82. PubMed ID: 1515098
[TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK.
Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y
Oncology; 1994; 51(3):296-302. PubMed ID: 8196915
[TBL] [Abstract][Full Text] [Related]
9. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.
D'Agostini C; Pica F; Febbraro G; Grelli S; Chiavaroli C; Garaci E
Int Immunopharmacol; 2005 Jul; 5(7-8):1205-12. PubMed ID: 15914325
[TBL] [Abstract][Full Text] [Related]
10. Interaction between thymic hormones and other immunomodulatory agents.
Mastino A; Favalli C; Grelli S; Garaci E
Ann Ist Super Sanita; 1991; 27(1):51-6. PubMed ID: 1958028
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
12. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Hedlund G
Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
[TBL] [Abstract][Full Text] [Related]
13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
14. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2.
Urano K; Habu S; Nishimura T
Cytokine; 1993 May; 5(3):224-9. PubMed ID: 8218934
[TBL] [Abstract][Full Text] [Related]
16. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.
Salvati F; Rasi G; Portalone L; Antilli A; Garaci E
Anticancer Res; 1996; 16(2):1001-4. PubMed ID: 8687090
[TBL] [Abstract][Full Text] [Related]
18. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
20. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
